A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Inclusion Criteria:
Exclusion Criteria:
info@adarx.com877-232-7974